American journal of translational research · 2026
Clinical efficacy and gastrointestinal hormonal effect of Lactobacillus rhamnosus combined with lactulose for treatment of irritable bowel syndrome with constipation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Rongfang, Pan Jindun
Аннотация
OBJECTIVE: This study aimed to explore the clinical efficacy of Lactobacillus rhamnosus combined with lactulose for the treatment of irritable bowel syndrome with constipation (IBS-C) and its effect on gastrointestinal hormones.
METHODS: A prospective, randomized, double-blind trial was conducted with three groups: control (n=45, mosapride citrate tablets), monotherapy (n=44, lactulose + control regimen), and combination (n=45, Lactobacillus rhamnosus + monotherapy regimen). The primary outcome measure was clinical efficacy. Secondary outcomes included the Bristol Stool Scale (BSS), Irritable Bowel Syndrome Quality of Life Score (IBS-QoL), Perceived Stress Scale (PSS), Irritable Bowel Syndrome Severity Score (IBS-SSS), gut microbiota, and gastrointestinal hormones assessed at days 0, 28, and 56, along with safety observations.
RESULTS: Following a 56-day intervention period, the combination group achieved 100.00% clinical effectiveness, significantly higher than the monotherapy (93.18%) or control groups (75.56%). Fecal consistency responders were 84.44% in the combination group vs. 47.73% (monotherapy) and 28.89% (control). The combination group showed higher IBS-QoL scores, lower PSS scores, and reduced IBS-SSS scores (P < 0.05). Intestinal flora analysis revealed decreased Ruminococcaceae and increased Fibrobacteraceae and Campylobacteraceae in the combination group. Gastrointestinal hormones improved, with increased motilin and decreased vasoactive intestinal peptide (P < 0.05). There was no significant difference in the incidence of adverse events among the three groups (P > 0.05).
CONCLUSION: Lactobacillus rhamnosus combined with lactulose significantly improves IBS-C symptoms and quality of life, and positively modulates intestinal flora and gastrointestinal hormones.
METHODS: A prospective, randomized, double-blind trial was conducted with three groups: control (n=45, mosapride citrate tablets), monotherapy (n=44, lactulose + control regimen), and combination (n=45, Lactobacillus rhamnosus + monotherapy regimen). The primary outcome measure was clinical efficacy. Secondary outcomes included the Bristol Stool Scale (BSS), Irritable Bowel Syndrome Quality of Life Score (IBS-QoL), Perceived Stress Scale (PSS), Irritable Bowel Syndrome Severity Score (IBS-SSS), gut microbiota, and gastrointestinal hormones assessed at days 0, 28, and 56, along with safety observations.
RESULTS: Following a 56-day intervention period, the combination group achieved 100.00% clinical effectiveness, significantly higher than the monotherapy (93.18%) or control groups (75.56%). Fecal consistency responders were 84.44% in the combination group vs. 47.73% (monotherapy) and 28.89% (control). The combination group showed higher IBS-QoL scores, lower PSS scores, and reduced IBS-SSS scores (P < 0.05). Intestinal flora analysis revealed decreased Ruminococcaceae and increased Fibrobacteraceae and Campylobacteraceae in the combination group. Gastrointestinal hormones improved, with increased motilin and decreased vasoactive intestinal peptide (P < 0.05). There was no significant difference in the incidence of adverse events among the three groups (P > 0.05).
CONCLUSION: Lactobacillus rhamnosus combined with lactulose significantly improves IBS-C symptoms and quality of life, and positively modulates intestinal flora and gastrointestinal hormones.